Organization (Hospital)
INSTITUT BERGONIE
ClinicalTrials.gov lists INSTITUT BERGONIE as lead sponsor of 119 trials. It has 266 active development programs and 37 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers INSTITUT BERGONIE: 119 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (70)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 31 |
| Sarcoma | 27 |
| Colorectal Neoplasms | 15 |
| Neoplasm Metastasis | 15 |
| Lung Neoplasms | 13 |
Showing 5 of 70 disease areas.
Trials by start year as sponsor or collaborator (27)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 6 |
| 2021 | 8 |
| 2020 | 6 |
| 2019 | 6 |
| 2018 | 4 |
| 2017 | 8 |
Showing 10 of 27 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 87 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (266)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| DOXORUBICIN | Sarcoma | Phase 3 | 3 |
| Cryoablation | Lung Neoplasms | Phase 3 | 1 |
| Ifosfamide or dacarbazine | Sarcoma | Phase 3 | 1 |
| At the discretion of the investigator | Sarcoma | Phase 3 | 1 |
| Cryoablation | Adenocarcinoma of Lung | Phase 3 | 1 |
Showing 5 of 266 active programs.
Approved assets (37)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DOXORUBICIN | 3 |
| CARBOPLATIN | 1 |
| PEMETREXED | 1 |
| Imatinib | 1 |
| PEMBROLIZUMAB | 1 |
Showing 5 of 37 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=58) | 31% on time (n=51) |
Journals published in (58)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of oncology : official journal of the European Society for Medical Oncology | 10 |
| European journal of cancer (Oxford, England : 1990) | 7 |
| Gynecologic oncology | 5 |
| European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 4 |
| Journal of geriatric oncology | 4 |
Showing 5 of 58 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 5 | 1 | 2024-02-20 |
Organization relationships (32)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| National Cancer Institute, France | Co sponsors trial with | 3 |
| Ministry of Health, France | Co sponsors trial with | 3 |
| Centre Hospitalier Universitaire, Amiens | Co sponsors trial with | 2 |
| Institut Curie | Co sponsors trial with | 2 |
| Assistance Publique – Hôpitaux de Paris | Co sponsors trial with | 2 |
Showing 5 of 32 relationships.
Latest dated events (135)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 135 events.
Biomarker capability evidence (249)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| A1CF | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 249 evidence rows.
Biomarkers this organization publishes on (462)
Shown in this order: most publications first.
Showing 5 of 462 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.